Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pre-emption On High: Supreme Court To Tackle Fraud Before Failure With Rezulin

Executive Summary

The U.S. Supreme Court is taking up a case that could limit when individuals can pursue state tort claims against drug manufacturers. On Sept. 25, the court granted Warner-Lambert's petition to hear a product liability case involving its diabetes drug Rezulin (troglitazone). At issue is whether federal law pre-empts a Michigan statute that allows someone to file a product liability claim if FDA has not found the manufacturer has concealed information from the agency
Advertisement

Related Content

FDA Preemption Cases Expected To Stay On Top Of Legal Calendar In 2008
FDA Preemption Cases Expected To Stay On Top Of Legal Calendar In 2008
FDA Preemption Policy Gets First Appeals Court Test With Zoloft, Paxil Cases
FDA Preemption Policy Gets First Appeals Court Test With Zoloft, Paxil Cases
Advertisement
UsernamePublicRestriction

Register

PS048845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel